Ticker

Brainstorm Cell Therapeutics (NASDAQ: BCLI - Get Free Report) and Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership. Profitability This table compares Brainstorm Cell

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company. Several research

Zealand Pharma A/S (ZLDPF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Zealand Pharma obesity drug showed disappointing weight loss in a Phase 2 trial.

The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.